

March 13, 2026

CDPH Recommends Immunizing Infants with RSV Monoclonal Antibodies through April 2026 – Continue Ordering RSV through VFC

Dear VFC Provider,

CDPH recommends continuing Respiratory Syncytial Virus (RSV) immunization of eligible infants and young children with RSV monoclonal antibody products through April 30, 2026, as RSV transmission is continuing in California.

As a result, RSV monoclonal antibody ordering will remain available through the VFC Program until the end of April. If you need additional RSV allocations to submit your order, please reach out to the VFC Program at myVFCvaccines@cdph.ca.gov.

CDPH Recommendations

- CDPH recommends continuing RSV immunization with RSV antibody products for another month, through April 30, 2026, to:
 - All infants aged 0 through 7 months, within 1 week of birth, ideally during the birth hospitalization or as soon as possible after discharge (unless prenatal RSV immunization occurred between 32 through 36 weeks of gestation and at least 14 days before delivery)
 - Nirsevimab or clesrovimab are recommended
 - Children aged 8 through 19 months at [high risk](#) of severe RSV
 - Only nirsevimab is recommended
- The Vaccines for Children (VFC) program provides nirsevimab and clesrovimab at no cost for providers immunizing children who are: Medi-Cal eligible, uninsured, underinsured (only at FQHCs/RHCs), and American Indian/Alaska Native.
- Under [AB144](#), California regulated health plans are required to cover RSV immunization based on CDPH guidance.
- CDPH continues to monitor RSV activity in California to guide recommendations for the remainder of the 2025-2026 season.

Thank you,



VFC

California Vaccines
for Children Program

California Department of Public Health, Immunization Branch
Vaccines for Children (VFC) Program
850 Marina Bay Parkway
Richmond, CA 94804

Phone: 877-2GET-VFC (877-243-8832)

Fax: 877-FAXX-VFC (877-329-9832)

Email: MyVFCVaccines@cdph.ca.gov

EZIZ.org